Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The EHA Research Roadmap: Malignant Lymphoid Diseases.
Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bödör C, Burkhardt B, Buske C, Dollores Caballero M, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Grønbæk K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-Guillermo A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trümper LH, Salles G. Dreyling M, et al. Among authors: jerkeman m. Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35620592 Free PMC article. No abstract available.
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S. Riihijärvi S, et al. Among authors: jerkeman m. Eur J Haematol. 2012 Nov;89(5):395-402. doi: 10.1111/ejh.12005. Epub 2012 Sep 14. Eur J Haematol. 2012. PMID: 22882209 Clinical Trial.
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M, Amador V, Callanan M, Jerkeman M, Le Gouill S, Pott C, Rule S, Zaja F; European Mantle Cell Lymphoma Network. Dreyling M, et al. Among authors: jerkeman m. Leuk Lymphoma. 2015 Apr;56(4):866-76. doi: 10.3109/10428194.2014.940584. Epub 2014 Aug 20. Leuk Lymphoma. 2015. PMID: 25015778
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.
Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Hoster E, et al. Among authors: jerkeman m. Leukemia. 2016 Jun;30(6):1428-30. doi: 10.1038/leu.2015.322. Epub 2015 Nov 24. Leukemia. 2016. PMID: 26598017 No abstract available.
Targeting of B-cell receptor signalling in B-cell malignancies.
Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L. Jerkeman M, et al. J Intern Med. 2017 Nov;282(5):415-428. doi: 10.1111/joim.12600. Epub 2017 Mar 14. J Intern Med. 2017. PMID: 28295729 Free article. Review.
198 results